. SlatteryMLKerberRA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA1993; 270: 1563–8
2.
. SwiftM. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet1986; 39: 573–83
3.
. SwiftMChaseCLMorrellD.Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet1990; 46: 21–7
4.
. FordDEastonDF. The genetics of breast and ovarian cancer. Br J Cancer1995; 72: 805–12
5.
. WeinbergRA. Oncogenes and tumor suppressor genes. CA Cancer J Clin1994; 44: 160–70
6.
. FordD. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet1994; 343: 692–5
7.
. ClausEBRischNThompsonWD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet1991; 48: 232–42
8.
. FordDEastonDFPetoJ.Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet1995; 57: 1457–62
9.
. ToninP. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med1996; 2: 1179–83
10.
. StruewingJP. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med1997; 336: 1401–8
11.
. CouchFJ. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med1997; 336: 1409–15
12.
. CouchFJWeberBL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat1996; 8: 8–18
13.
. SchragDKuntzKMGarberJEWeeksJC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med1997; 336: 1465–71
14.
. KeffordRTuckerKFriedlanderMKirkJ.Cancer in the family. Guidelines for general practice. Aust Fam Physician1997; 26: 545–9
15.
. PiverMSJishiMFTsukadaYNavaG.Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer1993; 71: 2751–5
16.
. CodoriAMBrandtJ.Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet1994; 54: 174–84
17.
. TibbenARoosRANiermeijerMF. Psychological consequences of presymptomatic testing for Huntington's disease [letter]. Lancet1997; 349: 809.
